OncRef

Clinical Trial: NCT03872947

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Toray Industries, Inc
Information Provided By:Toray Industries, Inc
Last Update Posted:2026-10-08

Study Overview

Brief Summary

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

Official Title

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Conditions

Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

Intervention / Treatment

  • Biological: TRK-950
  • Biological: TRK-950
  • Biological: TRK-950
  • Drug: Irinotecan
  • Drug: Leucovorin
  • Drug: 5-FU
  • Drug: Gemcitabine
  • Drug: Cisplatin
  • Drug: Carboplatin
  • Drug: Ramucirumab
  • Drug: Paclitaxel
  • Drug: Nivolumab
  • Drug: Pembrolizumab
  • Drug: Imiquimod Cream
  • Drug: Bevacizumab
  • Drug: PLD

Other Study ID Numbers

  • 950P1V02

Start Date (Actual)

2019-04-26

Primary Completion Date (Actual)

2026-07-16

Study Completion Date (Actual)

2026-07-16

Enrollment (Actual)

138

Study Type

Interventional

Phase

Phase 1